US · Healthcare · Medical Devices
EPS came in at 1.38 against a street estimate of 1.10 — a beat of 25.5%.
Analysts rate CONMED Corporation a hold (0 buy, 6 hold, 0 sell out of 6) with an average price target of $45.50.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.11% |
| Earnest Partners LLC | 8.58% |
| Vanguard Portfolio Management, LLC | 6.93% |
| Fuller & Thaler Asset Management Inc | 5.48% |
| Bank of America Corp | 4.68% |
| Vanguard Capital Management, LLC | 4.62% |
| State Street Corp | 4.62% |
| Dimensional Fund Advisors, Inc. | 4.40% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CONMED CORPORATION - Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net sales Q2 2026: $343.5 million (vs. $342.3 million Q2 2025) - essentially flat | 2026-07-29 |
| Results announced · Q3 2026 CONMED CORPORATION - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $343.5 million, up 0.3% year-over-year as reported; down 0.5% on | 2026-07-29 |
| Board / officer change · Q2 2026 CONMED CORPORATION FORM 8-K SUMMARY HEADLINE NUMBERS • New CFO appointment effective July 15, 2026: John E. Gallagher joins as Executive Vice Presid | 2026-06-17 |
| Material agreement · Q2 2026 CONMED CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company agreeing to repurchase approximately $645.2 million in aggregate principal amount o | 2026-06-04 |
| Material agreement · Q2 2026 CONMED CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • New debt facility: $450 million in incremental senior secured delayed draw Term A-2 Loan Fa | 2026-06-01 |
| Quarterly report · Q1 2026 CONMED CORPORATION – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net sales: $317.0 million (Q1 2026) vs. $321.3 million (Q1 2025) – down | 2026-04-30 |
| Proxy statement · Q2 2026 CONMED CORPORATION PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGES • Patrick J. Beyer became President and CEO in January 2025 (promoted from Chi | 2026-04-07 |
| Annual report FY2025 CONMED CORPORATION - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net Sales 2025: $1,374.7 million (up from $1,307.0 million in 2024 and $1, | 2026-02-17 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.20 / share ex-date Sep 15, 2025 · pay Oct 3, 2025 | 2025-09-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CONMED Corporation — free to start.
Google PlayApp StoreData updated 2026-09-18.